Great Diamond Partners’s Haemonetics HAE Stock Holding History

Great Diamond Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-231	Closed	-$26K	–	322
2019 Q4	$26K	Buy	+231	New	+$27.9K	0.01%	405

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Great Diamond Partners's HAE Position: Q1 2020 in Review

Great Diamond Partners sold out of Haemonetics (HAE) in Q1 2020, closing a stake of 231 shares — an estimated $26K sold.

Great Diamond Partners first reported a position in HAE in Q4 2019 and held it in 1 quarter. The position peaked at $26K in Q4 2019. 269 funds tracked by Wall St. Rank hold HAE as of Q1 2020.

Great Diamond Partners reported no remaining Haemonetics position as of Q1 2020 after selling out during the quarter.
Great Diamond Partners sold 231 Haemonetics shares in Q1 2020, an estimated $26K.
Great Diamond Partners first reported a position in Haemonetics in Q4 2019 and held it in 1 quarter.
Great Diamond Partners's Haemonetics position peaked at $26K in Q4 2019.
269 funds tracked by Wall St. Rank held Haemonetics as of Q1 2020.

Based on Great Diamond Partners's 13F filing for Q1 2020, filed 1 May 2020.